Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Bionovo, a drug discovery and development company, has reported promising data describing predictable estrogen regulatory elements that can be used to identify estrogenic drugs that are safer.
Subscribe to our email newsletter
The data showed that the new regulatory elements can distinguish the estrogenic pharmacological activity exerted by different compounds and allow for more accurate prediction of specific tissue effect.
The study was conducted by investigators at The Center for Reproductive Sciences in the department of obstetrics, gynecology and reproductive sciences at the University of California, San Francisco in collaboration with scientists at Bionovo.
Dale Leitman from the department of obstetrics, gynecology and reproductive sciences at the University of California, San Francisco, said: Selective estrogen modulators (SERMs) are an exciting class of drugs that are used to prevent breast cancer and osteoporosis and differ from estrogens in how they regulate gene transcription.
This study identified gene elements that are activated by SERMs but not by estrogens used in hormone therapy. The identification of these elements, coupled with the understanding of the differential regulation in various tissues by each estrogen receptor subtype, provides a new platform for the discovery of safer estrogenic drugs with SERM-like profiles to prevent and treat a variety of clinical conditions associated with menopause.
Isaac Cohen, chairman and CEO of Bionovo, said: The discovery of these selective estrogen regulatory elements strengthens our selective estrogen receptor modulator discovery engine. The advantage of the new array, of specific regulatory elements, is manifest in the pharmacological and toxicological insights gained.
We can now acquire higher predictive value and greater specificity from a complex biological system such as the regulation of the estrogen receptor pathways.
He also said that Bionovo is at the forefront of future SERM products which are far more specific and safe. It is a breakthrough for all future drugs that regulate the diverse effects of conditions affected by nuclear receptors and Bionovo is positioned to explore and exploit these pathways for many serious diseases with its expanded scientific collaborations, he added.